Upstream Bio Inc. UPB shares are trading lower during Friday’s session as the stock reacts to recent developments in its clinical trials. Over the last few days, the stock has plunged more than 54%.
Upstream Bio, Inc. UPB shares were trading higher during Wednesday’s premarket session following positive results from the Phase 2 VALIANT trial of verekitug, a treatment for severe asthma. The stock ...
Upstream Bio has sailed to a phase 2 win in sinusitis and plans to push its candidate forward against a competitive current. Investigators randomized 81 adults with chronic rhinosinusitis with nasal ...
New analyses of efficacy endpoints from the Phase 2 VIBRANT trial of verekitug in CRSwNP to be presented during the late-breaking poster session - ...
Upstream Bio, Inc. downgraded despite strong Verekitug phase 2 asthma results; assess anti-TSLP competition, dosing edge & catalysts. Click for this UPB update.
Upstream Hospitality Group has been recognized by Long Island Press as a 2025 Top Workplace, a distinction that honors companies fostering exceptional culture and employee satisfaction. Founded on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results